Navigation Links
Neurocrine Biosciences Amends Corporate Headquarters Lease
Date:10/1/2009

SAN DIEGO, Oct. 1 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company has entered into an amendment to its facility lease agreement. The amendment eliminates approximately 70,000 square feet of leased space.

"We worked with our landlord in a collaborative manner to reduce our leasing obligation and to allow them to directly market the property, while at the same time minimizing the cash flow impact to Neurocrine," said Timothy P. Coughlin, Vice President and Chief Financial Officer of Neurocrine Biosciences. "This is a significant first step in reducing our fixed real estate cost structure, reducing our overall obligation by approximately $27 million."

Under the terms of the lease amendment, Neurocrine will vacate the front building of the two building campus and will make an immediate payment of $4 million to the landlord as an initial release fee. Additionally, the Company has agreed to make certain rent payments and rent differential payments with respect to the released space.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH), irritable bowel syndrome (IBS) and other neurological and endocrine related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com

SOURCE Neurocrine Biosciences, Inc.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
2. Neurocrine Biosciences Secures Committed Equity Financing Facility
3. Neurocrine Biosciences Reports Second Quarter 2009 Results
4. Webcast Alert: Neurocrine Biosciences Announces 2nd Quarter 2009 Earnings Results
5. Neurocrine Biosciences Announces Conference Call and Webcast to Present Second Quarter 2009 Financial Results
6. Neurocrine Biosciences to Present at the 8th Annual Needham Life Sciences Conference
7. Neurocrine Biosciences to Present at the Deutsche Bank 34th Annual Health Care Conference
8. Neurocrine Biosciences Reports First Quarter 2009 Results
9. Neurocrine Announces Work Force Restructuring
10. Neurocrine Biosciences to Present at the 16th Annual Future Leaders in the Biotech Industry Conference
11. Neurocrine Biosciences to Present at the Cowen and Company 29th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... India , April 28, 2016 ... JT, Stirling, and Brayton Cryocoolers), Service (Technical Support, Product ... and Geography - Global Forecast to 2022", published by ... USD 2.94 Billion by 2022, at a CAGR of ... 70 market data Tables and 94 Figures spread through ...
(Date:4/28/2016)... Windsor, Connecticut (PRWEB) , ... April 28, 2016 ... ... Morris Group, Inc., will hold an open house for regional manufacturers at its ... and displays from Tsugami, Okuma, Hardinge Group, Chiron and Trumpf. Almost 20 ...
(Date:4/27/2016)... British Columbia , April 27, 2016 /PRNewswire/ ... oder "NanoStruck") (CSE: NSK) (OTCPink: NSKQB) ( ... im Anschluss an ihre Pressemitteilung vom 13. August ... erhalten hat, ihre Finanzen um zusätzliche 200.000.000 Einheiten ... 4.000.000 Kanadische Dollar zu bringen. Davon wurden 157.900.000 ...
(Date:4/27/2016)... , ... April 27, 2016 , ... ... simultaneous preclinical PET (Positron Emission Tomography) and MRI (Magnetic Resonance Imaging) in existing ... disease and testing novel treatments in small animal subjects. Simultaneous PET/MRI imaging offers ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
Breaking Biology News(10 mins):